科伦药业：与Crescent Biopharma合作 科伦博泰将收取8000万美元首付款

Core Viewpoint - Kolon Pharmaceutical's subsidiary, Kolon Biotech, has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, focusing on two drugs for solid tumors [1] Group 1: Partnership Details - The collaboration involves Kolon Biotech's SKB105 and Crescent's CR-001, both aimed at treating solid tumors [1] - Kolon Biotech grants Crescent exclusive rights in markets outside Greater China, while Crescent grants Kolon Biotech exclusive rights in Greater China [1] Group 2: Financial Terms - Kolon Biotech will receive an upfront payment of $80 million, along with up to $1.25 billion in milestone payments and royalties based on sales [1] - Crescent will receive an upfront payment of $20 million, with potential milestone payments of up to $30 million and royalties based on sales [1]